You are here:

caspofungin (Cancidas)

Advice

following an abbreviated submission:

caspofungin acetate (Cancidas®) is accepted for restricted use within NHS Scotland for the treatment of invasive candidiasis in paediatric patients (12 months to 17 years).

The Scottish Medicines Consortium has previously accepted this product for restricted use for this indication in adults.

Caspofungin provides an additional agent for the treatment of invasive candidiasis. Its use should be restricted to patients with fluconazole-resistant Candida infection who do not respond to, or cannot tolerate amphotericin B therapy or who are at an increased risk of serious side effects with amphotericin (eg. transplant patients, especially those receiving bone marrow transplants).

Drug Details

Drug Name: caspofungin (Cancidas)
SMC Drug ID: 552/09
Manufacturer: MSD
Indication: Invasive candidiasis in paediatric patients (12 months to 17 years).
BNF Category:
Sub Category: 5.2 Antifungal Drugs
Submission Type: Abbreviated Submission
Status: Restricted
Date Advice Published: 11 May 2009

Back